Arvinas to Present at Upcoming Investor Conferences
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced its participation in three upcoming investor conferences in September 2022. The conferences include the Citi 17th Annual BioPharma Conference on September 8, the Wells Fargo Healthcare Conference on September 9, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 12. Key executives will participate in fireside chats, with live webcasts available on their website. The company utilizes its proprietary PROTAC® technology to develop therapies for serious diseases.
- None.
- None.
NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in three upcoming investor conferences:
- Citi 17th Annual BioPharma Conference: Thursday, September 8 at 1:00 p.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
- 2022 Wells Fargo Healthcare Conference: Friday, September 9 at 9:45 a.m. ET. Sean Cassidy, chief financial officer, and Ron Peck, M.D., chief medical officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
- Morgan Stanley 20th Annual Global Healthcare Conference: Monday, September 12 at 11:05 a.m. ET. Ian Taylor, Ph.D., chief scientific officer, and Randy Teel, senior vice president, corporate and business development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
What conferences will Arvinas participate in September 2022?
Who from Arvinas will attend the Citi BioPharma Conference?
When is Arvinas' fireside chat at the Wells Fargo Healthcare Conference?
What is the focus of Arvinas' drug development?
Where can I find the live webcast for Arvinas' presentations?
